Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia2021 · 11 citations
2. 2Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)2022 · 1 citations
3. 3Apoptotic stress causes mtDNA release during senescence and drives the SASP2023 · 679 citations
4. 4Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML2023 · 36 citations
5. 5Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes2021 · 50 citations